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Hydroxytyrosol acetate (HT-AC) is a polyphenol present in virgin olive oil (VOO) at a proportion similar to hydroxytyrosol (HT) (160–479mmol/
kg oil). The present study was designed to measure the in vitro platelet antiaggregating activity of HT-AC in human whole blood, and compare this
effect with that of HT and acetylsalicylic acid (ASA). The experiments were designed according to the standard procedure to investigate the
activity of ASA. HT-AC and HT inhibited platelet aggregation induced by ADP, collagen or arachidonic acid in both whole blood and plate-
let-rich plasma (PRP). ASA and HT-AC had a greater effect in whole blood than in PRP when ADP or collagen was used as inducer. ASA
and HT-AC had a greater effect in PRP þ leucocytes than in PRP alone. All three compounds inhibited platelet thromboxane B2 and leucocyte
6-keto-prostaglandin F1a (6-keto-PF1a) production. The thromboxane/6-keto-PGF1a inhibition ratio (as an indirect index of the prostanoid equili-
brium) was 10·8 (SE 1) for HT-AC, 1·0 (SE 0·1) for HT and 3·3 (SE 0·2) for ASA. All three compounds stimulated nitric oxide production, although
HT was a weaker effect. In our experiments only concentrations higher than 500mM (HT) or 1 mM (HT-AC and ASA) inhibited 3-nitrotyrosine
production. All three compounds inhibited the production of TNFa by leucocytes, with no significant differences between them. In quantitative
terms HT-AC showed a greater antiplatelet aggregating activity than HT and a similar activity to that of ASA. This effect involved a decrease in
platelet thromboxane synthesis and an increase in leucocyte nitric oxide production.
Hydroxytyrosol acetate: Olive oil polyphenols: Platelet aggregation: Prostanoids: Nitric oxide
In the Mediterranean diet, which has been associated with a
reduced risk of CVD(1 – 4), olive oil is the main source of
fat. Although a variety of factors have been related with the
heart-healthy effect of this diet, there is broad agreement in
attributing a major role in this beneficial effect to the polyphe-
nols in virgin olive oil (VOO)(5). This effect may originate
from the action of polyphenols on different biochemical path-
ways, or from synergism between the effects of polyphenols
and fatty acids, particularly oleic acid (a MUFA)(6).
The polyphenol compound present in highest concentrations
in VOO is hydroxytyrosol (3,4-dihydroxyphenylethanol; HT);
its concentration varies depending on the variety of olive,
geographical area, ripeness of the fruit and method of olive
oil pressing, among other factors(7). For example, VOO from
Manzanilla variety contains 2·5–3 times as much HT
(479·6mmol/kg oil) as the Hojiblanca (159·2mmol/kg oil),
Picual (176·8mmol/kg oil), Cornicabra (164·1mmol/kg oil)
or Arbequina (179·6mmol/kg oil) varieties(7).
The effect of polyphenols on physiopathological mechanisms
involved in CVD has been characterized only in part. These
effects include inhibition of platelet aggregation(8,9), inhibition
of oxidation of LDL(10), stimulation of NO production(11) and
down-regulation of the expression of endothelial adhesion
molecules(12). Platelet aggregation is considered one of the
main events in arterial thrombosis, and this makes investigating
how aggregation is inhibited by polyphenols in VOO a worth-
while topic for further inquiry.
Although HT is the major polyphenol on VOO, other
polyphenols are present, including hydroxytyrosol acetate
(HT-AC)(7). The concentration of HT-AC is approximately
equal to that of HT in some olive varieties such as Arbequina,
but is twice as high as that of HT in the Picual variety, and
three to four times as high in the Manzanilla and Hojiblanca
varieties(7).
The aims of the present study were to measure the antipla-
telet aggregating effect in vitro of HT-AC in human blood,
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and to compare its effects to HT and acetylsalicylic acid
(ASA), the most widely used drug in the world to prevent
ischaemic CVD because of its antiplatelet aggregating action.
Experimental methods
Materials
Thromboxane B2, 6-keto-prostaglandin F1a (6-keto-PF1a) and
TNFa enzyme immunoassay kits were from Amersham Inter-
national plc (Little Chalfont, UK). Nitrite/nitrate and the
3-nitrotyrosine ELISA kits and HT were obtained from
Cayman Chemical (Ann Arbor, MI, USA). HT-AC was
supplied by the Department of Organic Chemistry and Phar-
maceutics, School of Pharmacy, University of Seville (Seville,
Spain). Collagen and ADP were obtained from Menarini
Diagno´stica S.A. (Barcelona, Spain). All other reagents were
from Sigma Chemical Co. (St. Louis, MO, USA).
Study design
The present in vitro study was carried out in blood samples
from healthy volunteers who had not taken any medication
during the 15 d before inclusion and VOO in the diet 24 h
before. Sodium citrate (3·8 %) at a proportion of 1:10 was
used as the anticoagulant. In each group of experiments we
used six samples from different volunteers (three men and
three women in each group) with a mean age of 32·8
(SE 1·3) years. The study was approved by the Clinical
Assays Committee of the Hospital Regional Universitario
Carlos Haya in Malaga, Spain.
Samples were used as whole blood, but in some exper-
iments, platelet-rich plasma (PRP), erythrocytes and leuco-
cytes were isolated from whole blood. PRP was obtained
after centrifugation of whole blood at 800 g for 10 min at
208C; all PRP samples were adjusted to 3 £ 109 platelets/l.
Erythrocytes were obtained from the pellet resulting from cen-
trifugation of whole blood to obtain PRP; erythrocytes were
washed twice with PBS (pH 7·4). Leucocytes were separated
on a Ficoll density gradient (Hystopaque 1077 and Hystopa-
que 1119) and diluted (final count: 5·2 (SE 0·2) £ 109 leuco-
cytes) in Ca2þ physiological saline solution (95 % viability
as judged by trypan blue exclusion).
Different concentrations of ASA, HT and HT-AC (1027 to
1023 M) were incubated at 378C before inducers were added.
All drugs were diluted in a mixture of ethanol–PBS (100ml
ethanol plus 900ml PBS) at a proportion of 1:10.
Analytical techniques
All techniques were run in a single-blind manner, i.e. the per-
sons who did the assays were unaware of the origin and nature
of the samples.
Platelet aggregometry
Platelet aggregation was measured as electronic impedance in
whole blood, PRP, PRP plus erythrocytes, and PRP plus leu-
cocytes (500ml sample diluted with 500ml PBS). We used a
Chrono-Log 540 aggregometer (Chrono-Log Corp., Haverton,
PA, USA) with collagen (1mg/ml), ADP (2·5mM) and
arachidonic acid (400mM) to induce aggregation. Drugs
were incubated at 378C for 10 min before the aggregation
inducer was added, and aggregation was recorded for
10 min. Maximum intensity of aggregation was quantified as
the maximum change in electronic impedance in samples
without the drug or a given concentration of each drug. The
concentrations of aggregating agents were chosen according
to previous experiments which yielded EC50 values of 1·10
(SE 0·14) mg/ml for collagen (n 10), 2·41 (SE 0·11) mM for
ADP and 385 (SE 21) mM for arachidonic acid (n 10). Eryth-
rocytes and leucocytes were added in a proportion to reach the
cell counts in whole blood (4·8 (SE 0·2) £ 1012 erythrocytes/l
and 6·0 (SE 0·4) £ 106 leucocytes/l).
Platelet production of thromboxane B2
The production of thromboxane A2 was determined by
measuring its stable metabolite thromboxane B2. Samples of
whole blood were stimulated with calcium ionophore
A23187 (50mM) at 378C during 30 min, then they were centri-
fuged at 10 000 g for 3 min, and the amount of thromboxane
B2 in the supernatant was determined with an enzyme immuno-
assay kit.
Leucocyte production of 6-keto-prostaglandin F1a
The production of prostacyclin was determined by measuring
its stable metabolite 6-keto-PF1a. We used samples of leuco-
cytes (6·5 (SE 0·4) £ 106 leucocytes/l) that were incubated
for 5 min at 378C, then 50mM-calcium ionophore A23187
was added and the samples were shaken for 30 min. The
samples were centrifuged at 10 000 g for 15 min at 48C, and
were frozen at 2808C until analysis for 6-keto-PF1a by
enzyme immunoassay.
Leucocyte production of nitric oxide
NO production was induced with the calcium ionophore
A23187 (50mM) and measured as nitrite þ nitrate concen-
tration in the supernatant of induced leucocyte samples (6·3
(SE 0·3) £ 106 leucocytes/l) with an enzyme immunoassay
kit. The experiments were designed to determine NO pro-
duction with the drug under study or in ethanol–PBS solution
(control sample) for 10 min at 378C. Briefly, leucocytes were
incubated for 10 min at 378C with 200ml buffer containing
10 mM-HEPES, 1 mM-EDTA, 1 mM-DL-dithiothreitol (DTT),
10mg/ml leupeptin, 4·8 mM-DL-valine, 1 mM-NADPH, 1 mM-
MgCl2, 1 mM-CaCl2 and 20mM-L-arginine, and then with
10ml saline or the corresponding concentration of the drugs.
Basal nitrite þ nitrate production was first determined; after
this step calcium ionophore A23187 was added and after
30 min of incubation at 378C the increase in nitrite þ nitrate
production was evaluated.
3-Nitrotyrosine and TNFa production
Blood was incubated with bacterial membrane lipopolysac-
charide (LPS; 1mg/ml) for 18 h at 378C. The plates were
then centrifuged, and the plasma was removed and frozen at
2808C. TNFa and 3-nitrotyrosine (an indicator of peroxyni-
trite production) were measured in the supernatant with a
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commercial enzyme immunoassay kit. In each experiment a
sample of blood without LPS induction was incubated, and
LPS-induced TNFa and 3-nitrotyrosine production was calcu-
lated as the difference between the LPS-induced samples and
non-induced samples.
Statistical analysis
The data are expressed as means and their standard errors for
ten experiments. All statistical analyses were done with the
Statistical Program for Social Sciences version 12.0 (SPSS
Inc., Chicago, IL, USA). One-way ANOVA followed by Bon-
ferroni transformation and unpaired Student’s t test were used,
and differences were considered significant when P,0·05.
Results
HT-AC and HT inhibited platelet aggregation induced by
ADP, collagen or arachidonic acid in a concentration-depen-
dent manner in whole blood and PRP (Figs. 1 and 2). Maxi-
mum intensity of aggregation in cultures induced with ADP
was 23·51 (SE 1·95) ohms in whole blood and 19·47
(SE 1·10) ohms in PRP. After induction with collagen, maxi-
mum aggregation was 21·24 (SE 1·16) ohms in whole blood
and 18·97 (SE 1·15) ohms in PRP, and in cultures induced
with arachidonic acid, maximum aggregation was 23·49
(SE 0·93) ohms in whole blood and 23·75 (SE 0·95) ohms in
PRP. Table 1 shows the concentrations of each compound
that inhibited maximum platelet aggregation in control
samples (incubated without the aggregation inducer) by
50 % (IC50). In whole blood, the antiplatelet aggregating
effect of HT was significantly weaker than that of HT-AC
or ASA. Inhibition of aggregation in whole blood was similar
with HT-AC and ASA except when arachidonic acid was
the inducer; in these experiments the antiaggregating effect
of ASA was stronger. In samples of PRP induced with
ADP or collagen we found no significant differences among
the three compounds, but when arachidonic acid was the
inducer, the effect of HT was significantly weaker than
HT-AC or ASA.
When we compared the antiaggregating effect in whole
blood and PRP, we found that the effect of HT-AC and
ASA was significantly stronger when aggregation was induced
with ADP or collagen (Table 1); the antiaggregating effect of
HT in whole blood was similar to that in PRP. In PRP incu-
bated with leucocytes the antiaggregating effect of HT-AC
and ASA increased in comparison to the effect in PRP alone
(Fig. 3). In PRP incubated with erythrocytes the antiaggregat-
ing effects of HT, HT-AC and ASA were not different statisti-
cally with respect to PRP. Maximum aggregation was 21·75
(SE 1·12) ohms in whole blood, 19·00 (SE 0·56) ohms in
PRP, 21·59 (SE 1·74) ohms in PRP with erythrocytes and
16·08 (SE 1·11) ohms in PRP with leucocytes.
All three compounds inhibited thromboxane B2 and 6-keto-
PF1a production in a concentration-dependent manner (Fig. 4).
Table 2 shows the IC50 values for these assays. The order of
potency in the inhibition of these two prostanoids was
ASA . HT-AC . HT. The thromboxane/prostacyclin inhi-
bition ratio was 10·79 (SE 1·03) for HT-AC, 1·05 (SE 0·09)
for HT and 3·28 (SE 0·21) for ASA. Thromboxane B2
production in control samples was 1·29 (SE 0·09) nmol/109
platelets and 6-keto-PF1a production was 1·16 (SE 0·09)
nmol/109 leucocytes.
All three compounds increased nitrite þ nitrate production
in whole blood in a concentration-dependent manner (Fig. 5),
although the effect of HT was significantly weaker than that
of HT-AC and ASA (Table 2). Nitrite þ nitrate concentration
in control samples was 1·05 ^ 0·01mmol/l. The production of
3-nitrotyrosine induced with LPS was significantly inhibited
only by the highest concentration of the compounds we
tested (1000mM) (Fig. 5; Table 2). The concentration of
Fig. 1. Platelet aggregation in human whole blood after incubation with
hydroxytyrosol acetate (B), hydroxytyrosol (X) and acetylsalicylic acid (V).
The inducers were ADP (2·5mM; A), collagen (1mg/ml; B) or arachidonic acid
(400mM; C). Values are means with their standard errors depicted by vertical
bars.
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3-nitrotyrosine in control samples was 39·85 (SE 3·28) nmol/l.
The production of TNFa was also inhibited in a concentra-
tion-dependent manner by all three compounds (Fig. 5),
with no significant differences among them (Table 2).
The concentration of TNFa in control samples was 10·36
(SE 1·21) pg/ml.
Discussion
We report the first evidence of the antiplatelet aggregating
effect of HT-AC in human blood. The effect of HT-AC was
stronger than that of HT and similar in quantitative terms to
that of ASA. Some phenolic compounds in VOO inhibit
platelet function, e.g., HT(8,9), oleuropein(8) and phenolic
isochromans(13). In fact, feeding VOO to rats or rabbits was
found to significantly reduce collagen-induced platelet aggre-
gation(14,15). The present results confirm this effect of HT, but
also show that HT-AC has a greater antiaggregating effect
than HT, and is almost as effective as ASA in blocking plate-
let aggregation. The latter observation is potentially important
because ASA is the most widely used drug in the world in pro-
phylaxis against thromboembolism.
In the present section we analyse the results obtained with
HT and HT-AC in relation to the mechanisms of action for
ASA, as the profile of inhibition of platelet aggregation of
HT-AC is similar to that of ASA (Table 1; Figs. 1 and 2).
Firstly, the main mechanism that explains the antithrombotic
effect of ASA is inhibiting the synthesis of thromboxane A2.
All three compounds inhibit thromboxane synthesis in a con-
centration-dependent manner. It was previously shown that
HT at a concentration of 400mM in whole blood reduced
collagen- or thrombin-induced thromboxane production by
approximately 75 %(8). Interpolating the results plotted in
Fig. 4 for a concentration of 400mM of the phenolic compounds
compared here shows that HT would reduce thromboxane pro-
duction by 67 % and HT-AC would reduce production by 86 %.
Secondly, the synthesis of thromboxane A2 can be reduced
by inhibition of the enzyme cyclooxygenase (as acting ASA)
or the enzyme thromboxane synthetase. The effect of HT
and HT-AC cannot be attributed to the inhibition of thrombox-
ane synthase activity, since prostacyclin production was also
inhibited (Fig. 4). The present finding suggests that cyclooxy-
genase was probably the target of these phenols. More than 30
years ago this mechanism of action was shown in ASA(16), and
it also appears to be important in the antiaggregating effect of
HT-AC. Although platelet thromboxane and leucocyte prosta-
cyclin production are not strictly comparable, they provide
an approximate idea of the effect of these compounds on
the thromboxane/prostacyclin balance through the IC50 prosta-
cyclin/IC50 thromboxane ratio (see Results).
Fig. 2. Platelet aggregation in human platelet-rich plasma after incubation
with hydroxytyrosol acetate (B), hydroxytyrosol (X) and acetylsalicylic acid
(V). The inducers were ADP (2·5mM; A), collagen (1mg/ml; B) or arachidonic
acid (400mM; C). Values are means with their standard errors depicted by
vertical bars.
Table 1. Concentrations of hydroxytyrosol acetate (HT-AC), hydroxytyr-
osol (HT) and acetylsalicylic acid (ASA) that inhibited 50 % of platelet
aggregation (IC50), induced with 2·5mM-ADP, 1mg/ml collagen or
400mM-arachidonic acid in whole-blood and platelet-rich plasma (PRP)‡
(Mean values with their standard errors)
IC50 (mM)
HT-AC HT ASA
Mean SE Mean SE Mean SE
ADP
Whole blood 94·17 7·58 738† 90 87·21 6·11
PRP 543* 35 625 85 813* 6·11
Collagen
Whole blood 26·48 1·66 195† 21 24·94 1·18
PRP 109* 9·64 109 11 281* 28
Arachidonic acid
Whole blood 40·08 4·10 197† 20 9·28 0·81
PRP 39·57 3·25 131† 15 6·64 0·40
Mean values were significantly different from those of whole blood (unpaired
Student’s t test): *P,0·0001.
Mean values were significantly different from those of ASA and HT-AC:
†P,0·0001.
‡ For details of subjects and procedures, see Experimental methods.
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HT-AC inhibited thromboxane production more than pros-
tacyclin production, an effect with clear benefits with a
view to preventing thrombosis. The cyclooxygenase-inhibiting
mechanism plays a potentially important role, since it was
recently shown that HT has no effect on other pathways invol-
ving platelets such as cAMP, at least not at a concentration of
100mM(9). The present findings are consistent with the weaker
antiaggregating effect of both phenolic compounds and ASA
when aggregation was induced by ADP, since the effect of
ADP is mainly the result of its ability to lower cytoplasmic
concentrations of cAMP(17,18). However, this is not to imply
that inhibition of thromboxane synthesis is the only mechan-
ism through which HT exerts its antithrombotic potential
in vivo, since it has also been shown to inhibit the expression
of adhesion molecules such as intercellular adhesion mol-
ecule-1 and vascular cell adhesion molecule-1 expressed on
endothelial cells(12).
Thirdly, other mechanisms can complete inhibition of
cyclooxygenase produced by HT and HT-AC. This is supported
in the differential antiaggregant effects in isolated platelets and
in whole blood. We found that HT had the same antiaggregating
effect in both media, whereas the effect of HT-AC and ASA
was stronger in whole blood, albeit with some exceptions.
When arachidonic acid was used as the inducer, aggregation
resulted from the stimulation of platelet thromboxane A2 syn-
thesis(19). The absence of differences in the antiaggregant
effect of ASA, HT and HT-AC is explained by the inhibition
of cyclooxygenase. The greater antiaggregating effect of ASA
and HT-AC in whole blood when platelets were induced with
ADP or collagen might be due to an effect on a different bio-
chemical pathway that mediates in the relations between leuco-
cytes, erythrocytes and platelets. In this connection it was found
that the greater effect of ASA in whole blood was mainly due to
the stimulation of neutrophil NO production(18,20), a finding
also reported for other salicylate derivatives(21).
Because erythrocytes did not modify the antiplatelet effect
of HT and HT-AC, leucocytes could probably influence this
effect through a modification in its NO production. ASA
Fig. 3. Maximum intensity of platelet aggregation (Imax) induced with
1mg/ml collagen in whole blood (WB), platelet-rich plasma (PRP), PRP plus
erythrocytes (PRP þ RBC) and PRP plus leucocytes (PRP þ L) after incu-
bation with hydroxytyrosol acetate (A), hydroxytyrosol (B) or acetylsalicylic
acid (C). Values are means with their standard errors depicted by vertical
bars. Mean values were significantly different from those of WB: *P,0·05,
**P,0·001. Mean values were significantly different from those of PRP:
þP,0·05, þþP,0·001.
Fig. 4. Whole-blood thromboxane B2 (A) and leucocyte keto-prostaglandin
F1a (B) induced with 50mM-calcium ionophore A23187 after incubation with
hydroxytyrosol acetate (B), hydroxytyrosol (X) and acetylsalicylic acid (V).
Values are means with their standard errors depicted by vertical bars.
Antiplatelet effect of hydroxytyrosol acetate 1161
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
and the two phenolic compounds stimulated leucocyte NO
production in a concentration-dependent manner (Fig. 5),
although the effect of HT was smaller in quantitative terms
than that of HT-AC or ASA. The reported ability of ASA to
stimulate NO production was confirmed by the present finding
that in PRP plus erythrocytes, the effect of ASA and HT-AC
was similar to their effect in PRP alone, whereas in PRP plus
leucocytes, the effect of HT-AC was similar to its effect in
whole blood, as was also noted for ASA in an earlier
report(18) and in the present study (Fig. 3). HT has been
shown to increase the cytoplasmic concentration of calcium
and thus contribute to the increase in NO synthesis by endo-
thelial cells(22,23). Our assays showed that HT-AC is also
able to stimulate calcium-dependent NO production in
human leucocytes.
Therefore, HT could inhibit platelet function in whole blood
through an inhibition of platelet thromboxane A2 synthesis,
while HT-AC could exert a greater antiaggregant effect
because of the inhibition of thromboxane A2 synthesis plus
an increase in NO leucocyte production, similar to the mech-
anism of action of ASA.
Fourthly, the effect of ASA on the production of inflamma-
tory mediators has been related to its action in preventing
CVD(24,25); accordingly, we tested TNFa production in leuco-
cytes stimulated with LPS. All three compounds compared
here inhibited the production of this inflammatory mediator
in a concentration-dependent way, with no differences
among them in the intensity of their effect. In this connection
it has been shown that exposure of LPS-induced human
THP-1 cells to olive vegetation water (containing approxi-
mately 200mM-polyphenols) reduced TNFa production by
50 %(26). In the present experimental procedure, the effect of
both HT and HT-AC was greater compared to the effect
reported by Bitler et al. (26) Therefore, in addition to the anti-
platelet effect of HT and HT-AC, it would be necessary to
consider its effect on inhibiting the production of inflamma-
tory mediators as an additional mechanism that could fill a
possible effect in the prevention of CVD, similar to ASA.
Finally, in the genesis and evolution of vascular disease
oxygen reactive species play an important role. In connection
with the production of NO, the presence of free radicals
facilitates peroxynitrite(27), we wished to study the potential
effect of free radicals on 3-nitrotyrosine formation as an
indirect indicator of peroxynitrite production(28). Despite the
antioxidant effect of polyphenols in VOO(29,30), these com-
pounds failed to inhibit peroxynitrite production, at least
under the present experimental conditions (Fig. 5). Moreover,
this antioxidant effect occurs in a range of concentrations
greater than the inhibition of platelet function, therefore it
does not appear that the antioxidant effect of these com-
pounds has a direct relationship with its antiplatelet effect.
In addition, blood samples used for platelet aggregation do
not have conditions for formation of free radicals, so the anti-
oxidant effect of HT and HT-AC could not influence their
antiplatelet effect.
The in vivo significance of the results presented here with
regard to inhibition of platelet aggregation by VOO phenols,
mainly HT and HT-AC, must be related to its pharmacokinetic
characteristics. After ingestion of 40 ml VOO with a phenolic
content of 366 mg/kg olive oil, maximal plasma concentration
of HT reached 25·83mg/l in man(31), which represents
approximately 130mmol HT/l. However, around 95 % of HT
is present in plasma in conjugate forms, suggesting an exten-
sive first pass intestinal/hepatic metabolism of the ingested
primary forms(32). According to these data only 1–2mmol
free HT/l is present in human plasma after ingestion of
VOO. Platelet aggregation curves obtained in the present
study show around 20–30 % inhibition, and the corresponding
thromboxane B2 production was 30–40 % for HT-AC (data
obtained by extrapolating the results at 1–2mmol/l). The poss-
ible inhibition of platelet function in the presystemic circula-
tion, as has been demonstrated for ASA(33), and the need to
investigate the pharmacokinetic parameters of the adminis-
tration of HT or HT-AC, remain to be established in order
to postulate the importance of these results in the prevention
of cardiovascular events.
In summary, the present results show that HT-AC, a poly-
phenol present in VOO, exerts an antiaggregating effect on
platelets that is greater in quantitative terms than the effect
of HT and similar to the effect of ASA. This effect involves
a decrease in platelet thromboxane synthesis and an increase
in leucocyte NO production. The present findings, together
with the reported antioxidant effect of HT-AC and its ability
to inhibit TNFa production, suggest the need for further
studies of the effect of HT-AC on the suite of mechanisms
that regulate thrombogenesis in man.
Table 2. Concentrations of hydroxytyrosol acetate (HT-AC), hydroxytyrosol (HT) and acetylsalicylic acid (ASA) that inhibited 50 % (IC50) calcium iono-
phore-induced thromboxane B2 and 6-keto-prostaglandin F1a (6-keto-PGF1a), lipopolysaccharide-induced 3-nitrotyrosine and TNFa, and concentrations
of these compounds that increased calcium ionophore-induced nitrite þ nitrate production by 50 % (EC50)‡
(Mean values with their standard errors)
HT-AC HT ASA
Mean SE Mean SE Mean SE
IC50 (mM)
Thromboxane B2 5·31 0·63 63·64* 4·84 1·37 0·09
6-Keto-PGF1a 58·33 6·00 69·40 6·41 4·53† 0·22
3-Nitrotyrosine .1000 658 26 .1000
TNFa 67·37 6·91 65·48 7·64 76·81 4·91
EC50 (mM)
Nitrites þ nitrates 1·79 0·15 101* 10 5·58 0·40
Mean values were significantly different from those of ASA and HT-AC: *P,0·0001.
Mean values were significantly different from those of HT and HT-AC: †P,0·0001.
‡ For details of subjects and procedures, see Experimental methods.
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